{"id":"NCT01832038","sponsor":"UCB Pharma SA","briefTitle":"Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures","officialTitle":"A Multi-center, Open-label, Uncontrolled, Long-term, Extension Study to Evaluate the Safety and Efficacy of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Partial-onset Seizures With or Without Secondary Generalization","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03-26","primaryCompletion":"2019-07-31","completion":"2019-07-31","firstPosted":"2013-04-15","resultsPosted":"2020-08-13","lastUpdate":"2021-08-17"},"enrollment":473,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy","Partial-onset Seizures"],"interventions":[{"type":"DRUG","name":"Lacosamide","otherNames":["Vimpat"]}],"arms":[{"label":"Lacosamide","type":"EXPERIMENTAL"}],"summary":"The purpose of this trial is to evaluate the safety and tolerability of long-term administration of Lacosamide at doses up to 400 mg/day in Japanese and Chinese adults with Epilepsy who have completed the Treatment and Transition Period of EP0008 \\[NCT01710657\\]","primaryOutcome":{"measure":"Number of Participants With at Least One Adverse Event Reported Spontaneously by the Subject or Observed by the Investigator From Baseline Until the End of Study Visit","timeFrame":"From Visit 1 (Week 0) up to approximately Week 323","effectByArm":[{"arm":"Lacosamide (SS)","deltaMin":410,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":67,"countries":["China","Japan"]},"refs":{"pmids":["34246118"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":83,"n":473},"commonTop":["Nasopharyngitis","Dizziness","Upper respiratory tract infection","Headache","Diarrhoea"]}}